Antithrombin III-Factor IIa complex (TAT) (TAT)

The Antithrombin III-Factor IIa complex, commonly referred to as the Thrombin-Antithrombin (TAT) complex, is a stable, inactive molecular assembly formed when the serine protease inhibitor antithrombin III neutralizes the procoagulant enzyme thrombin (Factor IIa). This complex formation is the primary physiological mechanism for regulating thrombin activity within the coagulation cascade, ensuring that clot formation remains localized and controlled (Source: StatPearls, "Antithrombin III", 2023). The rate of complex formation is naturally slow but is accelerated by several orders of magnitude in the presence of heparin or endogenous heparan sulfate proteoglycans, which act as templates for the binding of both proteins (Source: DrugBank, "Heparin", 2024). In clinical medicine, the TAT complex serves as a highly sensitive biomarker for the activation of the coagulation system, as its presence directly reflects the amount of thrombin that has been generated and subsequently inhibited in the blood (Source: Journal of Clinical Medicine, "Thrombin-Antithrombin Complex", 2021). Elevated TAT levels are diagnostic indicators for various thrombotic disorders, including deep vein thrombosis, pulmonary embolism, and disseminated intravascular coagulation (DIC) (Source: Clinical and Applied Thrombosis/Hemostasis, "TAT as a biomarker", 2019). While the complex itself is an inactive byproduct and not a target for direct inhibition, it is the functional endpoint for several major anticoagulant drugs, such as unfractionated heparin and low molecular weight heparins, which function by catalyzing the assembly of this complex to achieve their therapeutic effect (Source: DrugBank, "Heparin", 2024).

Other names

Thrombin-antithrombin complexTATTATCAntithrombin-thrombin complexATIII-FIIa complex

Heparin and its derivatives act as catalysts that bind to antithrombin III, inducing a conformational change that significantly accelerates its inhibition of thrombin, resulting in the formation of the inactive Antithrombin III-Factor IIa complex (Source: DrugBank, "Heparin", 2024).